루이소체 치매 치료 시장 규모, 점유율, 성장 분석 : 치료법별, 투여 경로별, 용도별, 구입 형태별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)

Global Lewy Body Dementia Treatment Market size was valued at USD 4.97 Billion in 2024 and is poised to grow from USD 5.25 Billion in 2025 to USD 8.12 Billion by 2033, growing at a CAGR of 5.6% during the forecast period (2026-2033).

The Global Lewy Body Dementia Treatment market encompasses a range of pharmaceuticals, biologics, and therapeutics aimed at addressing cognitive decline, visual hallucinations, and motor impairments related to this form of dementia, which ranks as the second most prevalent cause, affecting millions regionally. The market has seen significant advancement, facilitated by revised diagnostic criteria that enhance patient identification for clinical trials. This evolution has attracted major biotech firms into the research space, spurred by increased regulatory clarity. Contributing factors include an aging population and heightened awareness of LBD, which also encourage reimbursement from payers. Projected prevalence increases signify an urgent need for innovative diagnostic solutions, further driving drug development and creating opportunities for generic market entry as patents expire.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Lewy Body Dementia Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Lewy Body Dementia Treatment Market Segments Analysis

Global lewy body dementia treatment market is segmented by treatment modality, route of administration, application type, mode of purchase, end user and region. Based on treatment modality, the market is segmented into Pharmacological and Non-Pharmacological. Based on route of administration, the market is segmented into Oral, Transdermal Patch and Injectable. Based on application type, the market is segmented into Parkinson's Disease Dementia (PDD) and Dementia with Lewy Bodies (DLB). Based on mode of purchase, the market is segmented into Prescription and Over the Counter. Based on end user, the market is segmented into Hospitals, Specialty Clinics and Home Care. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Lewy Body Dementia Treatment Market

The rising prevalence of Lewy body dementia, driven by an aging population, is expanding the number of patients in need of effective treatment options. This demographic trend is prompting healthcare systems and pharmaceutical companies to focus on research and development initiatives, creating a conducive atmosphere for the emergence of novel drug pipelines. As healthcare professionals face a growing number of cases, the demand for effective therapies heightens, leading to greater investments in clinical programs and enhancing opportunities for innovative treatments to reach the market. Additionally, increased advocacy from patient groups is pushing for streamlined regulatory processes, further encouraging stakeholders to dedicate resources to this critical area of healthcare.

Restraints in the Global Lewy Body Dementia Treatment Market

The Global Lewy Body Dementia Treatment market faces significant challenges due to the difficulties in recruiting participants for clinical trials. The diagnostic complexities and varied presentation of the disease lead to many potential candidates being misdiagnosed or unaware of their condition, thereby shrinking the eligible volunteer pool. This limitation results in longer enrollment periods, increased study expenses, and potential compromises in statistical validity, which may deter sponsors from launching comprehensive research initiatives. As a consequence, the progress in therapeutic development is hindered, affecting market growth despite ongoing scientific interest. Additionally, the requirement for long-term follow-up to monitor disease progression poses further challenges for both participants and researchers, reducing the likelihood of enrollment.

Market Trends of the Global Lewy Body Dementia Treatment Market

The Global Lewy Body Dementia Treatment market is witnessing a significant shift towards precision medicine, characterized by the use of genomic and proteomic profiling to tailor therapeutics to specific patient subpopulations. This innovative approach enhances trial efficiency, expedites regulatory approvals, and allows for customized commercialization strategies. The rising trend of collaborations among biotech companies, academic institutions, and diagnostic firms is facilitating the development of companion diagnostics that further support individualized treatment plans. Additionally, the increased readiness of payers to reimburse therapies associated with validated biomarkers underscores a broader movement towards personalized care, shaping the landscape for Lewy body dementia treatments across various global markets.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Lewy Body Dementia Treatment Market Size by Treatment Modality & CAGR (2026-2033)

• Market Overview
• Pharmacological
  • Cognitive Therapy
  • Occupational Therapy
  • Physical Therapy
  • Speech Therapy
• Non-Pharmacological

Global Lewy Body Dementia Treatment Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Transdermal Patch
• Injectable

Global Lewy Body Dementia Treatment Market Size by Application Type & CAGR (2026-2033)

• Market Overview
• Parkinson's Disease Dementia (PDD)
• Dementia with Lewy Bodies (DLB)

Global Lewy Body Dementia Treatment Market Size by Mode of Purchase & CAGR (2026-2033)

• Market Overview
• Prescription
• Over the Counter

Global Lewy Body Dementia Treatment Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Clinics
• Home Care

Global Lewy Body Dementia Treatment Market Size & CAGR (2026-2033)

• North America (Treatment Modality, Route of Administration, Application Type, Mode of Purchase, End User)
  • US
  • Canada
• Europe (Treatment Modality, Route of Administration, Application Type, Mode of Purchase, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment Modality, Route of Administration, Application Type, Mode of Purchase, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment Modality, Route of Administration, Application Type, Mode of Purchase, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment Modality, Route of Administration, Application Type, Mode of Purchase, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Eisai Co. Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioArctic AB
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sumitomo Pharma Co. Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jazz Pharmaceuticals plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mallinckrodt Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cognition Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CervoMed Inc. (Neflamapimod)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Athenex Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• KeifeRx Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bausch Health Companies Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations